THE UNMET NEED
Exposure to radioactive elements is currently treated with decorporation agents that have to be administered intravenously. In situations where there may be mass casualties such as a nuclear accident or dirty bomb, IV administration is impractical. Capture Pharmaceuticals is developing an oral decorporation agent that can be distributed and administered easily; critical for the treatment of a large number of affected individuals.
Capture Pharmaceutical is also interested in removal of other non-radioactive toxic metals. Chief among these is gadolinium (Gd), a principal component of contrast agents used in Magnetic Resonance Imaging (MRI). There is a growing awareness of the potential for toxicity associated with the release of Gd ions from these MRI contrast agents and no current treatment available.
Capture is developing a drug called C2E2 for treatment of individuals who have been contaminated by radioactive elements, either by accident or following a nuclear terrorism event. C2E2 is a radionuclide decorporation agent that works by binding transuranic elements in the bloodstream and enhancing their elimination before they can be trapped inside critical organs where they can do significant damage. Because C2E2 can be taken orally, it has significant advantages for use in a mass casualty scenario over currently available products which must be administered by intravenous injection.
Additionally, C2E2 binds gadolinium, lead and mercury, all potentially toxic metals. C2E2 increases elimination of these elements from the bloodstream, reducing the toxic effects of contamination.
Michael Jay, Ph.D.
Co-founder and Chief Science Officer
Russell Mumper, Ph.D.
Alan Parr, Pharm.D., Ph.D.
Chief Operating Officer
Thomas Pitler, Ph.D.
Chief Executive Officer